Outlook Therapeutics Completes Federal Dispute Resolution (FDR) Meeting with FDA for ONS-5010/LYTENAVA™ (bevacizumab-vikg)
Summary
Formal decision expected in May 2026
Description
Formal decision expected in May 2026
Original reporting
AFBytes is a read-only aggregator. Use the original source for full context and complete reporting.
Open original source